Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia

被引：0
|
作者：
Seymour, John F. [1 ,2 ]
机构：
[1] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic 3000, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1128 / 1130
页数：3
相关论文
共 50 条
  • [1] Indirect treatment comparison analysis of venetoclax plus obinutuzumab with standard front-line regimens for chronic lymphocytic leukaemia
    Bastus, N. Coll
    Davids, M. S.
    Huntington, S. F.
    Moreno, C.
    Follows, G.
    Cuneo, A.
    Humphrey, K.
    Schary, W.
    Sail, K.
    Song, Y.
    Gao, Z.
    Tang, Z.
    Pena, G.
    Foa, R.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 219 - 220
  • [2] Front-Line Therapy for Chronic Lymphocytic Leukemia
    Desai, Sheetal
    Pinilla-Ibarz, Javier
    CANCER CONTROL, 2012, 19 (01) : 26 - 36
  • [3] ReVenG: A phase 2 study of venetoclax plus obinutuzumab retreatment in relapsed chronic lymphocytic leukaemia
    Davids, Matthew
    Fischer, Kirsten
    Robrecht, Sandra
    Zhang, Can
    Ahn, Inhye
    Lura, Michele Porro
    Sinai, Wendy
    Chyla, Brenda
    Sail, Kavita
    Pesko, John
    Pai, Madhavi
    Komlosi, Viktor
    Hallek, Michael
    Brown, Jennifer
    Al-Sawaf, Othman
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 149 - 150
  • [4] ReVenG: A phase 2 study of venetoclax plus obinutuzumab retreatment in relapsed chronic lymphocytic leukaemia
    Davids, Matthew
    Fischer, Kirsten
    Robrecht, Sandra
    Zhang, Can
    Ahn, Inhye
    Lura, Michele Porro
    Sinai, Wendy
    Chyla, Brenda
    Sail, Kavita
    Pesko, John
    Pai, Madhavi
    Komlosi, Viktor
    Hallek, Michael
    Brown, Jennifer
    Al-Sawaf, Othman
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 149 - 150
  • [5] Venetoclax plus rituximab for chronic lymphocytic leukaemia
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (05): : E233 - E233
  • [6] A new triplet for chronic lymphocytic leukaemia: zanubrutinib-venetoclax-obinutuzumab
    Rossi, Davide
    De Almeida, Joyce Marques
    LANCET HAEMATOLOGY, 2021, 8 (12): : E864 - E865
  • [7] Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain
    Moreno-Martinez, Estela
    de la Serna-Torroba, Javier
    Escudero-Vilaplana, Vicente
    Angel Hernandez-Rivas, Jose
    Sanchez-Cuervos, Marina
    Sanchez-Hernandez, Raquel
    FARMACIA HOSPITALARIA, 2022, 46 (03) : 121 - 132
  • [8] Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia
    Reagan, John L.
    Castillo, Jorge J.
    FUTURE ONCOLOGY, 2014, 10 (07) : 1147 - 1155
  • [9] Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia
    Stephens, Deborah M.
    BLOOD, 2019, 134 (20) : 1691 - 1696
  • [10] Venetoclax and obinutuzumab in chronic lymphocytic leukemia
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Dixon, Mark
    Bahlo, Jasmin
    Warburton, Simon
    Kipps, Thomas J.
    Weinkove, Robert
    Robinson, Sue
    Seiler, Till
    Opat, Stephen
    Owen, Carolyn
    Lopez, Javier
    Humphrey, Kathryn
    Humerickhouse, Rod
    Tausch, Eugen
    Frenzel, Lukas
    Eichhorst, Barbara
    Wendtner, Clemens-M.
    Stilgenbauer, Stephan
    Langerak, Anton W.
    van Dongen, Jacque J. M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Goede, Valentin
    Mobasher, Mehrdad
    Hallek, Michael
    BLOOD, 2017, 129 (19) : 2702 - 2705
12345